Marisa Wexler, MS, senior science writer —

The prevalence of Lambert-Eaton myasthenic syndrome (LEMS) in Japan is similar to that of other countries, affecting approximately 2.7 out of every one million people in the country. That is according to a study, “Nationwide survey of Lambert-Eaton myasthenic syndrome in Japan,” published in the journal…

The diagnostic journey of a man in his early 30s with progressive muscle weakness that was ultimately determined to be due to Lambert-Eaton myasthenic syndrome (LEMS) was described in a recent case report. The report, “Progressive motor quadriparesis with wasting: a diagnostic conundrum,” was published in BMJ Case…

In a deal that ends a three-year U.S. court battle over patent infringement claims for Lambert-Eaton myasthenic syndrome (LEMS) medications, Catalyst Pharmaceuticals will acquire the rights to the LEMS therapy Ruzurgi. Catalyst announced it has reached a settlement with Jacobus Pharmaceutical and PANTHERx Rare on its patent…

A company called Vibe Biotechnology has launched to build a community of patients, scientists, and other partners to find cures for rare diseases like Lambert-Eaton myasthenic syndrome (LEMS). “The challenge for rare diseases isn’t necessarily finding a treatment — it’s funding it,” Alok Tayi, PhD, co-founder and CEO of…

Long-term treatment with Firdapse is generally well-tolerated by people with Lambert-Eaton myasthenic syndrome (LEMS), according to a study of patient registry data. “The European LEMS registry aimed to collate observational safety data on treatments offered to patients with LEMS, particularly [Firdapse], which was approved in the year before…

The potential risks and benefits of several policy changes that could affect the landscape of developing treatments for rare diseases like Lambert-Eaton myasthenic syndrome (LEMS) were discussed in a recent white paper. The paper, “The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability,” was…

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

A branch of the European Medicines Agency (EMA) has recommended that Amifampridine SERB, a generic version of Firdapse, be approved to treat adults with Lambert‑Eaton myasthenic syndrome (LEMS) in the European Union. The recommendation, from the EMA’s Committee for Medicinal Products for Human Use (CHMP), will now…

The Federal Court of Canada has issued a decision that, for the second time, sets aside Health Canada’s approval of Ruzurgi (amifampridine) to treat Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 and older. The decision is a legal victory for Catalyst Pharmaceuticals and its Canadian sublicensee, KYE…

Catalyst Pharmaceuticals has secured three new U.S. patents covering the use of Firdapse (amifampridine) for treating Lambert-Eaton myasthenic syndrome (LEMS). The United States Patent and Trademark Office informed Catalyst that one new patent will be issued on March 8 and two more a week later on March 15.